Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

NCT01616524 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

880

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus (HCV)

Interventions

BIOLOGICAL: Pegylated interferon lambda (pegIFNλ)
BIOLOGICAL: Pegylated interferon lambda (pegIFNλ)
BIOLOGICAL: Pegylated interferon alfa-2a (pegIFNα-2a)
DRUG: Ribavirin
DRUG: Ribavirin
DRUG: Daclatasvir
DRUG: Placebo matching Daclatasvir

Sponsor

Bristol-Myers Squibb